Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/05/22
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022GlobeNewsWire • 05/03/22
Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewsWire • 03/01/22
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/27/22
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/24/22
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022GlobeNewsWire • 02/16/22
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022GlobeNewsWire • 12/21/21
Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare ConferenceGlobeNewsWire • 12/01/21
Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye DiseaseGlobeNewsWire • 11/24/21
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021GlobeNewsWire • 11/09/21
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/07/21
Oyster Point Pharma's TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye DiseaseGlobeNewsWire • 11/03/21
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021GlobeNewsWire • 11/02/21
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye DiseasePRNewsWire • 10/18/21
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Oyster Point Inks License Pact With Ji Xing Pharma For Dry Eye Disease Candidates In Greater ChinaBenzinga • 08/06/21
Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/05/21